Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. ("PetMed" or the "Company") (NASDAQ: PETS).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS).  Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. ("PetMed" or the "Company") (NASDAQ: PETS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS).  Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

MIAMI--(BUSINESS WIRE)--Cardone Ventures, backed by billionaire investor, Grant Cardone and his business partners Brandon and Natalie Dawson, today announced that it has submitted an unsolicited, non-binding proposal to acquire PetMed Express, Inc. (Nasdaq: PETS) (“PetMeds”) for $4.25 per share in cash, representing an implied equity value of approximately $89 million. The proposal was delivered to the Board of Directors of PetMed Express and is not subject to any financing contingency, reflect.

NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. ("PetMed" or the "Company") (NASDAQ: PETS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

DELRAY BEACH, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company” or “PetMeds”), today confirmed that it has received an unsolicited and non-binding acquisition proposal from SilverCape Investments Limited, a Singapore-based investment firm, to acquire all of the outstanding shares of the Company for $4 per share in cash, subject to various conditions such as due diligence and the execution of a mutually acceptable definitive agreement, but not subject to any financing contingency.